Qoliana is owned by Sandoz Inc.
Qoliana contains Brimonidine Tartrate.
Qoliana has a total of 1 drug patent out of which 0 drug patents have expired.
Qoliana was authorised for market use on 22 May, 2006.
Qoliana is available in solution/drops;ophthalmic dosage forms.
The generics of Qoliana are possible to be released after 19 August, 2025.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7265117 | SANDOZ INC | Topical brimonidine tartrate formulations that lack chlorine dioxide |
Aug, 2025
(2 years from now) |
Drugs and Companies using BRIMONIDINE TARTRATE ingredient
Market Authorisation Date: 22 May, 2006
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
2
United States
1
Canada
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic